Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Fineline Cube Feb 3, 2026
Company Deals

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases

Fineline Cube Feb 3, 2026
Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Fineline Cube Feb 2, 2026
Company Deals

Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia

Fineline Cube Feb 2, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Fineline Cube Feb 3, 2026
Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Fineline Cube Feb 3, 2026
Company Drug

Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE

Fineline Cube May 28, 2024

Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...

Company Drug

Hinova Pharmaceuticals to Present HP518 Data at ASCO, Marking First-in-Human Trial Milestone

Fineline Cube May 28, 2024

Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, is scheduled to present data...

Company Drug

Henlius Biotech’s Biosimilar Rituximab Receives First Overseas Marketing Approval from Peru

Fineline Cube May 28, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696), a biopharmaceutical company based in China, has announced...

Company Drug

Hotgen Biotech Receives FDA Clearance to Initiate Clinical Trials for SGC001

Fineline Cube May 28, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Company Drug

Innovent Biologics’ Picankibart Achieves Positive Results in Phase III Psoriasis Trial

Fineline Cube May 28, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced the successful...

Company Drug

Luye Pharma’s Subsidiary Gets NMPA Green Light for Biosimilar Xgeva

Fineline Cube May 28, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a controlling subsidiary of China-based Luye Pharma Group...

Company Medical Device

Blue Sail Medical Receives NMPA Approval for Disposable Coronary Intravascular Impact Waveguide

Fineline Cube May 28, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that it has received marketing...

Company Drug

RareStone Group’s Pitolisant Secures NMPA Approval to Treat Narcolepsy in Children and Adolescents

Fineline Cube May 28, 2024

RareStone Group, a China-based company specializing in rare diseases (formerly known as Citrine Medicine), has...

Company Drug

Sanofi’s Sarclisa Receives FDA Priority Review for Newly Diagnosed Multiple Myeloma Treatment

Fineline Cube May 28, 2024

Sanofi plc (NYSE: SNY), a leading pharmaceutical company based in France, has announced that the...

Company Policy / Regulatory

Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026

Fineline Cube May 27, 2024

The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate...

Company Drug

Yantai Dongcheng Pharmaceutical Receives NMPA Approval for SSTR2 Targeted Radioactive Drug

Fineline Cube May 27, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Deals

Medilink Therapeutics Partners with BioNTech to Develop ADC Products Using TMALIN Technology

Fineline Cube May 27, 2024

Medilink Therapeutics, based in Suzhou, has entered into another partnership agreement with German biotechnology company...

Company Drug

Jiangsu Hengrui’s SHR-A1921 Anticipated to Gain NMPA Breakthrough Designation for Ovarian Cancer

Fineline Cube May 27, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its drug candidate SHR-A1921 is...

Company Drug

Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024

Fineline Cube May 27, 2024

A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...

Company Drug

Novartis’ Fabhalta Shows Promise in Late-Stage C3 Glomerulopathy Trial

Fineline Cube May 27, 2024

Novartis AG (NYSE: NVS), a leading Swiss pharmaceutical company, last week announced positive preliminary data...

Company Drug

Kexing Pharmaceutical Secures NMPA Approval for Childhood Growth Hormone Deficiency Study

Fineline Cube May 27, 2024

Kexing Pharmaceutical (SHA: 688136), based in China, has received approval from the National Medical Products...

Company Drug

Henlius Biotech’s Denosumab Biosimilar Secures EMA Review for European Market Entry

Fineline Cube May 27, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...

Company Deals

Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board

Fineline Cube May 27, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation...

Company Deals

Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China

Fineline Cube May 27, 2024

Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for BAT6005 and BAT1308 Combination Therapy Trial

Fineline Cube May 27, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Posts pagination

1 … 306 307 308 … 618

Recent updates

  • Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation
  • Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China
  • SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
  • Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
  • Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.